View ValuationAbera Bioscience 将来の成長Future 基準チェック /06現在、 Abera Bioscienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長33.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.3m). Market cap is less than US$100m (kr135.7m market cap, or US$14.7m).お知らせ • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.3m). Market cap is less than US$100m (kr129.1m market cap, or US$13.7m).New Risk • Feb 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr17m revenue, or US$1.9m). Market cap is less than US$100m (kr132.2m market cap, or US$14.7m).お知らせ • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026New Risk • Oct 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (kr16m revenue, or US$1.7m). Market cap is less than US$100m (kr117.1m market cap, or US$12.4m).お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025お知らせ • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025お知らせ • Apr 10Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox TechnologyOrexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (kr69.5m market cap, or US$7.10m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.5m).New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr86.0m market cap, or US$8.04m). Minor Risk Revenue is less than US$5m (kr13m revenue, or US$1.2m).お知らせ • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.5m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr59.9m market cap, or US$5.45m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (kr13m revenue, or US$1.1m).お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024お知らせ • Apr 16Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024お知らせ • Jan 24Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024お知らせ • Oct 16Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023お知らせ • Jul 18Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023お知らせ • Jan 25Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023Board Change • Nov 16No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • May 24Insider recently bought kr161k worth of stockOn the 17th of May, Magnus Linderoth bought around 20k shares on-market at roughly kr7.88 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Nov 03We're Not Very Worried About Abera Bioscience's (NGM:ABERA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Jul 21We Think Abera Bioscience (NGM:ABERA) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Feb 25Abera Bioscience AB has completed an IPO in the amount of SEK 24.081 million.Abera Bioscience AB has completed an IPO in the amount of SEK 24.081 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,490,000 Price\Range: SEK 6.9 Transaction Features: Sponsor Backed Offering このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Abera Bioscience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NGM:ABERA - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202612-16-11-10N/A12/31/202512-10-4-3N/A9/30/202517-101N/A6/30/202516-156N/A3/31/202516-1-10N/A12/31/202415-1-10N/A9/30/202413-4-9-8N/A6/30/20249-8-12-12N/A3/31/20245-13-15-15N/A12/31/20233-17-18-18N/A9/30/20230-19-18-18N/A6/30/20231-19-20-20N/A3/31/20231-20-20-20N/A12/31/20222-19-20-20N/A9/30/20222-17-16-16N/A6/30/20222-15-15-15N/A3/31/20221-11-9-9N/A12/31/20211-9-10-10N/A9/30/20211-8-10-10N/A6/30/20211-7-6-6N/A3/31/20210-6-5-5N/A12/31/20201-4-3-3N/A11/30/20201-3-2-2N/A12/31/20192-2N/A-3N/A12/31/20182-3N/A-2N/A12/31/20171-2N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ABERAの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ABERAの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ABERAの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ABERAの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ABERAの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ABERAの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 09:24終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Abera Bioscience AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Niklas ElmhammerCarlsquare ABHerman KuntscherCarlsquare AB
New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.3m). Market cap is less than US$100m (kr135.7m market cap, or US$14.7m).
お知らせ • Apr 13Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026
New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$5m (kr12m revenue, or US$1.3m). Market cap is less than US$100m (kr129.1m market cap, or US$13.7m).
New Risk • Feb 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 34% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (34% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr17m revenue, or US$1.9m). Market cap is less than US$100m (kr132.2m market cap, or US$14.7m).
お知らせ • Jan 13Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026
New Risk • Oct 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (kr16m revenue, or US$1.7m). Market cap is less than US$100m (kr117.1m market cap, or US$12.4m).
お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025
お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025
お知らせ • Apr 14Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025
お知らせ • Apr 10Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox TechnologyOrexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements.
New Risk • Apr 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (kr69.5m market cap, or US$7.10m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.5m).
New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.5m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr86.0m market cap, or US$8.04m). Minor Risk Revenue is less than US$5m (kr13m revenue, or US$1.2m).
お知らせ • Jan 15Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025
New Risk • Nov 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.5m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr59.9m market cap, or US$5.45m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.1% increase in shares outstanding). Revenue is less than US$5m (kr13m revenue, or US$1.1m).
お知らせ • Oct 15Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024
お知らせ • Jul 23Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024
お知らせ • Apr 16Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024
お知らせ • Jan 24Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024
お知らせ • Oct 16Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023
お知らせ • Jul 18Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023
お知らせ • Jan 25Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023
Board Change • Nov 16No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • May 24Insider recently bought kr161k worth of stockOn the 17th of May, Magnus Linderoth bought around 20k shares on-market at roughly kr7.88 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Nov 03We're Not Very Worried About Abera Bioscience's (NGM:ABERA) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Jul 21We Think Abera Bioscience (NGM:ABERA) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Feb 25Abera Bioscience AB has completed an IPO in the amount of SEK 24.081 million.Abera Bioscience AB has completed an IPO in the amount of SEK 24.081 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,490,000 Price\Range: SEK 6.9 Transaction Features: Sponsor Backed Offering